Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

27.4%

17 terminated/withdrawn out of 62 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

10%

6 trials in Phase 3/4

Results Transparency

53%

9 of 17 completed trials have results

Key Signals

13 recruiting9 with results11 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2

31(51.7%)

Phase 1

22(36.7%)

Phase 3

6(10.0%)

Early Phase 1

1(1.7%)

60Total

Phase 2(31)

Phase 1(22)

Phase 3(6)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (62)

Showing 20 of 62 trials

NCT05864534Phase 2Active Not Recruiting

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Role: collaborator

NCT07227636Phase 2Recruiting

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Role: collaborator

NCT06843551Phase 2Recruiting

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Role: collaborator

NCT07735624Phase 2Recruiting

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Role: collaborator

NCT03495882Phase 1Completed

A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Role: lead

NCT05318469Phase 1Recruiting

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Role: collaborator

NCT06411691Phase 1Recruiting

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Role: collaborator

NCT07152821Phase 3Terminated

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Role: collaborator

NCT05632328Phase 2Active Not Recruiting

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Role: collaborator

NCT06346197Phase 3Recruiting

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Role: collaborator

NCT06076837Phase 1Terminated

The Seven Trial: Exploiting the Unfolded Protein Response

Role: collaborator

NCT06843434Phase 2Recruiting

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Role: collaborator

NCT05630183Phase 2Completed

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Role: lead

NCT05891821Phase 2Recruiting

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Role: collaborator

NCT06322108Phase 2Active Not Recruiting

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Role: collaborator

NCT05571293Phase 2Active Not Recruiting

Combination Immunotherapy in Colorectal Cancer

Role: collaborator

NCT06751524Unknown

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Role: lead

NCT06300463Phase 2Recruiting

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Role: collaborator

NCT07128355Early Phase 1Recruiting

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

Role: collaborator

NCT05363709Phase 2Withdrawn

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Role: collaborator